Clinical Characteristics, Patterns of Use, and incidence of Adverse Events in Patients With Nonvalvular Atrial Fibrillation Treated With Oral Anticoagulants in Colombia

References

• Molteni M, Polo Friz H, Primitz L, et al. The definition of valvular and non-valvular atrial fibrillation: results of a physicians’ survey. Europace. 2014;16(12):1720–1725.
   PubMed Web of Science ®Google Scholar
• Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–272. doi:10.1378/chest.09-1584
   PubMed Web of Science ®Google Scholar
• Olesen JB, Lip GY, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost. 2011;106(4):739–749. doi:10.1160/TH11-05-0364
   PubMed Web of Science ®Google Scholar
• Banerjee A, Lane DA, Torp-Pedersen C, et al. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost. 2012;107(3):584–589. doi:10.1160/TH11-11-0784
   PubMed Web of Science ®Google Scholar
• Lip GYH, Keshishian A, Kang A, et al. Effectiveness and safety of oral anticoagulants among non-valvular atrial fibrillation patients with polypharmacy. Eur Heart J Cardiovasc Pharmacother. 2021;7(5):405–414. doi:10.1093/ehjcvp/pvaa117
   PubMed Web of Science ®Google Scholar
• Pinto DA, Sánchez-Vallejo CA, Pedraza AL, et al. Description of patients with non-valvular atrial fibrillation admitted to the emergency room. Rev Colomb Cardiol. 2016;23(4):270–276.
   Google Scholar
• Archontakis-Barakakis P, Li W, Kalaitzoglou D, et al. Effectiveness and safety of intracranial events associated with the use of direct oral anticoagulants for atrial fibrillation: a systematic review and meta-analysis of 92 studies. Br J Clin Pharmacol. 2022;88(11):4663–4675. doi:10.1111/bcp.15464
   PubMed Web of Science ®Google Scholar
• Machado-Alba JE, Gaviria-Mendoza A, Machado-Duque ME, et al. Use of non-vitamin K antagonist oral anticoagulants in Colombia: a descriptive study using a national administrative healthcare database. Pharmacoepidemiol Drug Saf. 2021;30(4):426–434. doi:10.1002/pds.5124
   PubMed Web of Science ®Google Scholar
• Nguyen TN, Hilmer SN, Cumming RG. Review of epidemiology and management of atrial fibrillation in developing countries. Int J Cardiol. 2013;167(6):2412–2420. doi:10.1016/j.ijcard.2013.01.184
   PubMed Web of Science ®Google Scholar
• Rosselli D, Rodríguez AJ, García ÁA, et al. Atrial fibrillation prevalence in a Colombian university hospital. Rev Colom Cardiol. 2013;20(6):383–385.
   Google Scholar
• Franco JS, Vizcaya D. Availability of secondary healthcare data for conducting pharmacoepidemiology studies in Colombia: a systematic review. Pharmacol Res Perspect. 2020;8(5):e00661. doi:10.1002/prp2.661
   PubMed Web of Science ®Google Scholar
• Medina-Morales DA, Machado-Duque ME, Gaviria-Mendoza A, et al. Clinical characteristics and stratification of the cerebrovascular accident risk among patients with atrial fibrillation in Colombia, 2011–2016. Expert Rev Cardiovasc Ther. 2021;19(2):181–187. doi:10.1080/14779072.2021.1873766
   PubMed Web of Science ®Google Scholar
• Sakuma I, Uchiyama S, Atarashi H, et al. Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis. Heart Vessels. 2019;34(11):1839–1851. doi:10.1007/s00380-019-01425-x
   PubMed Web of Science ®Google Scholar
• Brown JD, Shewale AR, Dherange P, et al. A comparison of oral anticoagulant use for atrial fibrillation in the pre- and post-DOAC Eras. Drugs Aging. 2016;33(6):427–436. doi:10.1007/s40266-016-0369-y
   PubMed Web of Science ®Google Scholar
• Bodega F, Russi A, Melillo F, et al. INSigHT (Italian DOACs San Raffaele Hospital) registry investigators. Direct oral anticoagulants in patients with nonvalvular atrial fibrillation and extreme body weight. Eur J Clin Invest. 2022;52(1):e13658. doi:10.1111/eci.13658
   PubMed Web of Science ®Google Scholar
• Gedikli Ö, Altay S, Ünlü S, et al. Real-life data of major and minor bleeding events with direct oral anticoagulants in the one-year follow-up period: the NOAC-Turk study. Anatol J Cardiol. 2021;25(3):196–204. doi:10.5152/AnatolJCardiol.2021.57635
   PubMed Web of Science ®Google Scholar
• Almas T, Musheer A, Ejaz A, et al. Efficacy and safety of direct oral anticoagulants with and without Aspirin: a systematic review and Meta-analysis. Int J Cardiol Heart Vasc. 2022;40:101016. doi:10.1016/j.ijcha.2022.101016
   PubMed Web of Science ®Google Scholar
• van den Ham HA, Souverein PC, Klungel OH, et al. Major bleeding in users of direct oral anticoagulants in atrial fibrillation: a pooled analysis of results from multiple population-based cohort studies. Pharmacoepidemiol Drug Saf. 2021;30(10):1339–1352. doi:10.1002/pds.5317
   PubMed Web of Science ®Google Scholar
• Lobraico-Fernandez J, Baksh S, Nemec E. Elderly bleeding risk of direct oral anticoagulants in nonvalvular atrial fibrillation: a systematic review and meta-analysis of cohort studies. Drugs R D. 2019;19(3):235–245. doi:10.1007/s40268-019-0275-y
   PubMed Web of Science ®Google Scholar
• Giner-Soriano M, Cortes J, Gomez-Lumbreras A, et al. The use and adherence of oral anticoagulants in primary health care in catalunya, Spain: a real-world data cohort study. Aten Primaria. 2020;52(8):529–538. doi:10.1016/j.aprim.2020.05.016
   PubMed Web of Science ®Google Scholar
• Hindricks G, Potpara T, Dagres N, et al.; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European heart rhythm association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498. doi:10.1093/eurheartj/ehaa612
   PubMed Web of Science ®Google Scholar
• Rogula S, Gąsecka A, Mazurek T, et al. Safety and efficacy of DOACs in patients with advanced and end-stage renal disease. Int J Environ Res Public Health. 2022;19(3):1436. doi:10.3390/ijerph19031436
   PubMed Web of Science ®Google Scholar
• Ellinghaus P, Perzborn E, Hauenschild P, et al. Expression of pro-inflammatory genes in human endothelial cells: comparison of rivaroxaban and dabigatran. Thromb Res. 2016;142:44–51. doi:10.1016/j.thromres.2016.04.008
   PubMed Web of Science ®Google Scholar
• Ishibashi Y, Matsui T, Yamagishi S. Apixaban exerts anti-inflammatory effects in mesangial cells by blocking thrombin/protease-activated receptor-1 system. Thromb Res. 2014;134(6):1365–1367. doi:10.1016/j.thromres.2014.09.028
   PubMed Web of Science ®Google Scholar
• Machado-Alba JE, Machado-Duque ME, Gaviria-Mendoza A. Extreme polypharmacy: the need to mint a new term. Pharmacoepidemiol Drug Saf. 2020;29(2):224–225. doi:10.1002/pds.4942
   PubMed Web of Science ®Google Scholar
• Castro-Rodríguez A, Machado-Duque ME, Gaviria-Mendoza A, et al. Factors related to excessive polypharmacy (≥15 medications) in an outpatient population from Colombia. Int J Clin Pract;2018. e13278. doi:10.1111/ijcp.13278
   PubMed Web of Science ®Google Scholar
• Machado-Duque ME, Castaño-Montoya JP, Medina-Morales DA, et al. Drugs with anticholinergic potential and risk of falls with hip fracture in the elderly patients: a case-control study. J Geriatr Psychiatry Neurol. 2018;31(2):63–69. doi:10.1177/0891988718757370
   PubMed Web of Science ®Google Scholar
• Machado-Duque ME, Castaño-Montoya JP, Medina-Morales DA, et al. Association between the use of benzodiazepines and opioids with the risk of falls and Hip fractures in older adults. Int Psychogeriatr. 2018;30(7):941–946. doi:10.1017/S1041610217002745
   PubMed Web of Science ®Google Scholar
• Lip GY, Clementy N, Pericart L, et al. Stroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation: the Loire Valley atrial fibrillation project. Stroke. 2015;46(1):143–150. doi:10.1161/STROKEAHA.114.007199
   PubMed Web of Science ®Google Scholar
• Steinberg BA, Kim S, Thomas L, et al. Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators and Patients. Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF) registry. Circulation. 2014;129(20):2005–2012. doi:10.1161/CIRCULATIONAHA.114.008643
   PubMed Web of Science ®Google Scholar
• Sanghai SR, Liu W, Wang W, et al. Prevalence of frailty and associations with oral anticoagulant prescribing in atrial fibrillation. J Gen Intern Med. 2022;37(4):730–736. doi:10.1007/s11606-021-06834-1
   PubMed Web of Science ®Google Scholar
• Sasaki S, Sotomi Y, Hirata A, et al. Comparison of low-dose direct oral anticoagulants for patients <80 Versus ≥80 years of age with atrial fibrillation. Am J Cardiol. 2022;162:86–91. doi:10.1016/j.amjcard.2021.09.019
   PubMed Web of Science ®Google Scholar
• Zhang XL, Zhang XW, Wang TY, et al. Off-label under- and overdosing of direct oral anticoagulants in patients with atrial fibrillation: a meta-analysis. Circ Cardiovasc Qual Outcomes. 2021;14(12):e007971. doi:10.1161/CIRCOUTCOMES.121.007971
   PubMed Web of Science ®Google Scholar
• Toorop MMA, Chen Q, Tichelaar VYIG, et al. Predictors, time course, and outcomes of persistence patterns in oral anticoagulation for non-valvular atrial fibrillation: a Dutch nationwide cohort study. Eur Heart J. 2021;42(40):4126–4137. doi:10.1093/eurheartj/ehab421
   PubMed Web of Science ®Google Scholar
• Banerjee A, Benedetto V, Gichuru P, et al. Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study. Heart. 2020;106(2):119–126. doi:10.1136/heartjnl-2019-315307
   PubMed Web of Science ®Google Scholar
• Hadžibegović I, Jurin I, Letilović T, et al. Changes of recommended anticoagulation therapy in patients with atrial fibrillation and high thrombotic risk: long-term follow-up data from two hospital centers. Expert Rev Cardiovasc Ther. 2021;19(9):857–863. doi:10.1080/14779072.2021.1962293
   PubMed Web of Science ®Google Scholar
• Kirchmayer U, Narduzzi S, Mayer F, et al. Safety and effectiveness of direct oral anticoagulants versus vitamin K antagonists: results from 3 Italian regions. Recenti Prog Med. 2019;110(4):195–202. doi:10.1701/3154.31345
   PubMedGoogle Scholar
• ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010;159(3):340–347.e1. doi:10.1016/j.ahj.2009.11.025
   PubMed Web of Science ®Google Scholar
• Bahit MC, Lopes RD, Wojdyla DM, et al. Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. Int J Cardiol. 2013;170(2):215–220. doi:10.1016/j.ijcard.2013.10.062
   PubMed Web of Science ®Google Scholar
• Carnicelli AP, Hong H, Connolly SJ, et al. COMBINE AF (A collaboration between multiple institutions to better investigate non-vitamin K antagonist oral anticoagulant use in atrial fibrillation) investigators. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex. Circulation. 2022;145(4):242–255. doi:10.1161/CIRCULATIONAHA.121.056355
   PubMed Web of Science ®Google Scholar